
Targacept, Inc.
200 East First Street, Suite 300Winston-Salem, NC 27101-4165 Therapeutic Focus:Central nervous system diseases and disordersTherapeutic Targets: Neuronal nicotinic receptors (NNRs), which are key regulators of the nervous systemProduct Candidates: TC-5214, major depressive disorder and resistant hypertension; AZD3480 (TC-1734), one or both of Alzheimer's disease and ADHD; TC-5619, cognitive dysfunction in schizophrenia or one or more other indications characterized by cognitive impairment; AZD1446 (TC-6683), Alzheimer's disease, ADHD or one or more other indications characterized by cognitive impairment; and TC-2216/TC-5685, depression/anxiety disorders. |
President & CEO: J. Donald deBethizy, Ph.D.
![]() |
Strategic Alliances:
Exclusive global license and research collaboration with AstraZeneca AB for the development and commercialization of AZD3480 (TC-1734) to treat Alzheimer’s disease, adult ADHD, and cognitive disorders, as well as a multi-year research collaboration.
In addition, as of November 2007, AstraZeneca secured a future option for an exclusive license to TC-5619.
Exclusive global strategic alliance with GlaxoSmithKline focused in five therapeutic areas: pain, smoking cessation, obesity, addiction and Parkinson's disease.
Intellectual Property: PentadTM, a proprietary drug discovery platform; and an extensive patent estate covering compounds that act on NNRs
Product:
Inversine® (mecamylamine HCl), indicated for the treatment of moderately severe to severe essential hypertension and for uncomplicated cases of malignant hypertension
Intellectual Property: PentadTM, a proprietary drug discovery platform; and an extensive patent estate covering compounds that act on NNRs


